P
Palvella Therapeutics, Inc. (PVLA)
NCM – Real vaqt narxi. Valyuta: USD
125.79
+3.70 (3.03%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
125.79
+3.70 (3.03%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Palvella Therapeutics, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, jiddiy va kam uchraydigan genetik teri kasalliklari bilan og'rigan bemorlarni davolash uchun yangi terapiyalarni ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniyaning asosiy mahsulot nomzodi QTORIN rapamycin bo'lib, bu yangi, 3,9% suvsiz topik jeli bo'lib, u mikrokistik limfatik malformatsiyalarni davolash uchun 3-faza klinik sinovidan o'tmoqda, shuningdek, teri venoz malformatsiyalarini davolash uchun 2-faza klinik sinovidan o'tmoqda. Shuningdek, u angiokeratomalar va boshqa mTOR-faollashgan teri kasalliklarini davolash uchun QTORIN rapamycinni; va tarqalgan sirt aktinik porokeratozini davolash uchun QTORIN pitavastatinni ishlab chiqadi. Kompaniya Ueyn, Pensilvaniya shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jeffrey Martini Ph.D. | Chief Scientific Officer |
| Mr. Jason Burdette | SVP of CMC & Technical Operations |
| Mr. Kent Taylor | Senior Vice President of Sales |
| Mr. Matthew E. Korenberg | CFO, Corporate Secretary & Treasurer |
| Mr. Wesley H. Kaupinen | Founder, President, CEO & Director |
| Ms. Ashley Hartmann Kline M.B.A. | Chief Commercial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | pvla-20260507.htm |
| 2026-05-07 | 10-Q | pvla-20260331.htm |
| 2026-04-30 | DEF 14A | tm261617-1_def14a.htm |
| 2026-04-13 | 8-K | pvla-20260413.htm |
| 2026-04-07 | 8-K | pvla-20260407.htm |
| 2026-03-31 | 8-K | pvla-20260331.htm |
| 2026-02-26 | 8-K | tm2534019d6_8k.htm |
| 2026-02-24 | 8-K | pvla-20260224.htm |
| 2026-01-29 | 8-K | pvla-20260129.htm |
| 2026-01-12 | 8-K | pvla-20260112.htm |
| Ms. Bohan Wei | Vice President of Corporate Development & New Product Planning |
| Ms. Emily Cook | Senior Vice President of Clinical Operations |
| Ms. Kathleen Goin | Chief Operating Officer |
| Ms. Sarah Foster | Senior Vice President of Human Resources |